Evidence map›Paper›PMID 21207959›Full record

ArticleJournal of medicinal chemistry2011

Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.

Fabrice G Siméon, Matthew T Wendahl, Victor W Pike

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fabrice G SiméonMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Room B3C346A, 10 Center Drive, Bethesda, MD 20892-1003, USA. simeonf@mail.nih.gov
Matthew T Wendahl
Victor W Pike

Funding

PET Radiopharmaceutical SciencesZIAMH002793 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PIKE, VICTOR W · 2009 to 2025
$69.8M
Intramural NIH HHS Z99 MH999999NIMH NIH HHS N01 MH032004
6 · The paper itself

Abstract

The structure of the potent selective mGlu(5) ligand, SP203 (1, 3-fluoro-5-[[2-(fluoromethyl)thiazol-4-yl]ethynyl]benzonitrile), was modified by replacing the 2-fluoromethyl substituent with an amino or halo substituent and by variation of substituents in the distal aromatic ring to provide a series of new high-affinity mGlu(5) ligands. In this series, among the most potent ligands obtained, the 2-chloro-thiazoles 7a and 7b and the 2-fluorothiazole 10b showed subnanomolar mGlu(5) affinity. 10b also displayed >10000-fold selectivity over all other metabotropic receptor subtypes plus a wide range of other receptors and binding sites. The 2-fluorothiazoles 10a and 10b were labeled using [(18)F]fluoride ion (t(1/2) = 109.7 min) in moderately high radiochemical yield to provide potential radioligands that may resist troublesome radiodefluorination during the imaging of brain mGlu(5) with position emission tomography. The iodo compound 9b has nanomolar affinity for mGlu(5) and may also serve as a lead to a potential (123)I-labeled ligand for imaging brain mGlu(5) with single photon emission computed tomography.

Indexed as

AnimalsBrainFluorine RadioisotopesIodine RadioisotopesPositron-Emission TomographyRadiopharmaceuticalsRatsReceptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateStructure-Activity RelationshipThiazolesTomography, Emission-Computed, Single-Photon3-((2-fluorothiazol-4-yl)ethynyl)-5-fluorobenzonitrile3-((2-fluorothiazol-4-yl)ethynyl)benzonitrile3-((2-iodothiazol)-4-ethynyl)-5-fluorobenzonitrileFluorine RadioisotopesIodine RadioisotopesRadiopharmaceuticalsReceptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateThiazoles

Identifiers

PMID21207959
PMCPMC3092816

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.